Efficacy of cannabidiol treatment in experimental MS is due to immunosuppressive activity of myeloid cells in CNS downregulating recruitment of CD4+ T cells, proinflammatory chemokines and gasdermin D expression
Authors: Nicholas Dopkins, Kiesha Wilson, Kathryn Miranda, Prakash S Nagarkatti and Mitzi Nagarkatti Published in The Journal of Immunology May 2020 Abstract Cannabidiol (CBD) is a nonpsychoactive ingredient from…